Use of a dual hypocretin antagonist in shift workers to improve their daytime sleep


  • This pilot study found that suvorexant, a dual hypocretin antagonist, increases the length of daytime sleep in shift workers compared to placebo. Larger trials are needed to compare suvorexant with current standard therapies.

Why this matters

  • Shift workers often have difficulty sleeping because of a misalignment of the internal circadian clock with sleep and wake behavior. While several techniques exist to increase daytime sleep in shift workers, they have limited success.

  • Hypocretins are excitatory neuropeptides that mediate wake promotion, this study finds that blocking hypocretin-1 using suvorexant increases daytime sleep in shift workers.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.